Literature DB >> 4907812

Hypotension caused by L-dopa.

D B Calne, J Brennan, A S Spiers, G M Stern.   

Abstract

In 20 patients with idiopathic Parkinsonism maximum tolerated doses of L-dopa were found to induce a mean reduction in blood pressure (erect systolic) of 19.3 mm.Hg, without any significant change in pulse rate. This hypotension may be due to dopamine, acting on adrenergic nerve endings or on the central nervous system itself.

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 4907812      PMCID： PMC1699425          DOI： 10.1136/bmj.1.5694.474

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


  11 in total

1.  NOREPINEPHRINE SYNTHESIS AND RELEASE IN VIVO MEDIATED BY 3,4-DIHYDROXYPHENETHYLAMINE.

Authors:  W H HARRISON; M LEVITT; S UDENFRIEND
Journal:  J Pharmacol Exp Ther       Date:  1963-11       Impact factor: 4.030

2.  The action of sympathomimetic amines in animals treated with reserpine.

Authors:  J H BURN; M J RAND
Journal:  J Physiol       Date:  1958-12-04       Impact factor: 5.182

3.  A neurological syndrome associated with orthostatic hypotension: a clinical-pathologic study.

Authors:  G M SHY; G A DRAGER
Journal:  Arch Neurol       Date:  1960-05

4.  Lithium.

Authors:  F K Goodwin; D L Murphy; W E Bunney
Journal:  Lancet       Date:  1969-07-26       Impact factor: 79.321

5.  L-dopa in postencephalitic parkinsonism.

Authors:  D B Calne; G M Stern; D R Laurence; J Sharkey; P Armitage
Journal:  Lancet       Date:  1969-04-12       Impact factor: 79.321

6.  Parkinsonism and DOPA.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene; R B Aronson
Journal:  Trans Assoc Am Physicians       Date:  1968

7.  The potential role of dopamine in the treatment of shock.

Authors:  L I Goldberg; R C Talley; J L McNay
Journal:  Prog Cardiovasc Dis       Date:  1969-07       Impact factor: 8.194

8.  The release of 3H-dopamine from the isolated rabbit ileum.

Authors:  G G Collins; G B West
Journal:  Br J Pharmacol       Date:  1968-11       Impact factor: 8.739

9.  L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism.

Authors:  M D Yahr; R C Duvoisin; M M Hoehn; M J Schear; R E Barrett
Journal:  Trans Am Neurol Assoc       Date:  1968

10.  Renin-aldosterone system in Parkinson's disease.

Authors:  A Barbeau; L Gillo-Joffroy; R Boucher; W Nowaczynski; J Genest
Journal:  Science       Date:  1969-07-18       Impact factor: 47.728
View more
  48 in total

1.  Inhibition by dopamine of 3H-noradrenaline release elicited by nerve stimulation in the isolated cat's nictitating membrane.

Authors:  M A Enero; S Z Langer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1975       Impact factor: 3.000

2.  Cardiovascular reflexes in Parkinson's disease: effect of domperidone and apomorphine.

Authors:  M Merello; Z Pirtosek; S Bishop; A J Lees
Journal:  Clin Auton Res       Date:  1992-08       Impact factor: 4.435

3.  Nonmotor outcomes in Parkinson's disease: is deep brain stimulation better than dopamine replacement therapy?

Authors:  Rupam Borgohain; Rukmini Mridula Kandadai; Afshan Jabeen; Meena A Kannikannan
Journal:  Ther Adv Neurol Disord       Date:  2012-01       Impact factor: 6.570

4.  Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat.

Authors:  J P M Finberg; A Gross; O Bar-Am; R Friedman; Y Loboda; M B H Youdim
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

5.  Cardiovascular reflexes and autonomic dysfunction in Parkinson's disease.

Authors:  G Meco; L Pratesi; V Bonifati
Journal:  J Neurol       Date:  1991-07       Impact factor: 4.849

6.  The protein Ocular albinism 1 is the orphan GPCR GPR143 and mediates depressor and bradycardic responses to DOPA in the nucleus tractus solitarii.

Authors:  Y Hiroshima; H Miyamoto; F Nakamura; D Masukawa; T Yamamoto; H Muraoka; M Kamiya; N Yamashita; T Suzuki; S Matsuzaki; I Endo; Y Goshima
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

7.  Sympathetic vasoconstrictor reflexes in Parkinson's disease with autonomic dysfunction.

Authors:  E B Andersen; F Boesen
Journal:  Clin Auton Res       Date:  1997-02       Impact factor: 4.435

8.  Incidence of side effects from levodopa during the introduction of treatment.

Authors:  R B Godwin-Austen; C C Frears; S Bergmann
Journal:  Br Med J       Date:  1971-01-30

9.  The cardiovascular effects of L-dopa in the pithed rat.

Authors:  E Eden; P A Nasmyth
Journal:  Br J Pharmacol       Date:  1974-08       Impact factor: 8.739

10.  Cause of death among patients with Parkinson's disease: a rare mortality due to cerebral haemorrhage.

Authors:  S Iwasaki; Y Narabayashi; K Hamaguchi; A Iwasaki; M Takakusagi
Journal:  J Neurol       Date:  1990-04       Impact factor: 4.849
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.